HERSHBERG ROBERT 4

What Happened

• Robert Hershberg, a director of Recursion Pharmaceuticals (RXRX), was granted 88,424 restricted stock units (RSUs) on June 17, 2026. The filing reports an acquisition price of $0.00 (i.e., an award/grant rather than a purchase).
• The RSUs will vest on the earlier of June 17, 2027 or the day before the company's 2027 annual meeting, subject to Hershberg's continued service (per the footnote). This award is a compensation grant to a director—not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-17; Price reported: $0.00; Shares awarded: 88,424 RSUs.
• Shares owned after the transaction: not specified in the Form 4 filing.
• Footnote: Grant made under the Issuer's Outside Director Compensation Policy; vesting tied to continued service and the earlier of June 17, 2027 or the day before the 2027 annual meeting.
• Filing timeliness: Transaction reported on Form 4 filed 2026-06-22 for a 2026-06-17 grant — the filing was later than the typical 2-business-day window for insiders (i.e., appears to be a late filing).

Context

• RSUs are a form of equity compensation that convert into shares upon vesting and may be forfeited if the director leaves before vesting; they are routine director compensation and do not directly signal a buy/sell decision by the insider.
• Tax withholding or share settlement may occur at vesting; the filing does not indicate immediate sale or further disposition.